Transgene Past Earnings Performance
Past criteria checks 0/6
Transgene's earnings have been declining at an average annual rate of -37.8%, while the Biotechs industry saw earnings growing at 15.3% annually. Revenues have been growing at an average rate of 2.4% per year.
Key information
-37.8%
Earnings growth rate
-35.7%
EPS growth rate
Biotechs Industry Growth | 30.8% |
Revenue growth rate | 2.4% |
Return on equity | -143.0% |
Net Margin | -282.6% |
Next Earnings Update | 14 May 2024 |
Recent past performance updates
Recent updates
Downgrade: Here's How Analysts See Transgene SA (EPA:TNG) Performing In The Near Term
Mar 21Transgene SA (EPA:TNG) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Mar 19Does Transgene (EPA:TNG) Have A Healthy Balance Sheet?
Mar 18Transgene (EPA:TNG) Has Debt But No Earnings; Should You Worry?
Nov 24Health Check: How Prudently Does Transgene (EPA:TNG) Use Debt?
Apr 16What Type Of Shareholders Own The Most Number of Transgene SA (EPA:TNG) Shares?
Mar 12Does Transgene's (EPA:TNG) Share Price Gain of 62% Match Its Business Performance?
Jan 23Revenue & Expenses BreakdownBeta
How Transgene makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 8 | -22 | 7 | 0 |
30 Sep 23 | 8 | -28 | 7 | 0 |
30 Jun 23 | 9 | -33 | 7 | 0 |
31 Mar 23 | 10 | -33 | 8 | 0 |
31 Dec 22 | 10 | -33 | 8 | 0 |
30 Sep 22 | 14 | -28 | 8 | 0 |
30 Jun 22 | 18 | -23 | 8 | 0 |
31 Mar 22 | 18 | -21 | 8 | 0 |
31 Dec 21 | 17 | -20 | 7 | 0 |
30 Sep 21 | 13 | -23 | 7 | 0 |
30 Jun 21 | 9 | -27 | 6 | 0 |
31 Mar 21 | 9 | -22 | 6 | 0 |
31 Dec 20 | 10 | -17 | 7 | 0 |
30 Sep 20 | 12 | -11 | 7 | 0 |
30 Jun 20 | 14 | -6 | 7 | 0 |
31 Mar 20 | 14 | -12 | 7 | 0 |
31 Dec 19 | 13 | -19 | 7 | 0 |
30 Sep 19 | 11 | -6 | 7 | 0 |
30 Jun 19 | 8 | 8 | 8 | 0 |
31 Mar 19 | 8 | 8 | 7 | 0 |
31 Dec 18 | 7 | 8 | 7 | 0 |
30 Sep 18 | 7 | -10 | 6 | 4 |
30 Jun 18 | 7 | -29 | 6 | 9 |
31 Mar 18 | 7 | -31 | 6 | 15 |
31 Dec 17 | 7 | -32 | 6 | 22 |
30 Sep 17 | 8 | -32 | 6 | 22 |
30 Jun 17 | 9 | -31 | 6 | 22 |
31 Mar 17 | 9 | -28 | 6 | 20 |
31 Dec 16 | 10 | -24 | 6 | 18 |
30 Sep 16 | 10 | -26 | 6 | 19 |
30 Jun 16 | 9 | -28 | 6 | 20 |
31 Mar 16 | 9 | -33 | 6 | 22 |
31 Dec 15 | 10 | -38 | 6 | 24 |
30 Sep 15 | 10 | -40 | 6 | 25 |
30 Jun 15 | 10 | -42 | 7 | 26 |
31 Mar 15 | 11 | -41 | 7 | 26 |
31 Dec 14 | 11 | -41 | 8 | 27 |
30 Sep 14 | 13 | -41 | 7 | 28 |
30 Jun 14 | 15 | -41 | 7 | 30 |
31 Mar 14 | 15 | -42 | 7 | 32 |
31 Dec 13 | 16 | -43 | 7 | 34 |
30 Sep 13 | 15 | -44 | 7 | 34 |
30 Jun 13 | 14 | -45 | 7 | 34 |
Quality Earnings: TNG is currently unprofitable.
Growing Profit Margin: TNG is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: TNG is unprofitable, and losses have increased over the past 5 years at a rate of 37.8% per year.
Accelerating Growth: Unable to compare TNG's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: TNG is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.3%).
Return on Equity
High ROE: TNG has a negative Return on Equity (-143.02%), as it is currently unprofitable.